机译:阶段第3阶段对骨髓瘤升降治疗阶段的存活结果的最终分析
Hop Claude Huriez Serv Malad Sang Lille France;
Univ Athens Sch Med Dept Clin Therapeut Athens Greece;
Mayo Clin Rochester MN USA;
Frankston Hosp Frankston Australia;
Cross Canc Inst Edmonton AB Canada;
Bologna Univ Sch Med Seragnoli Inst Hematol Bologna Italy;
Fdn Pascale NCI Dept Hematol &
Dev Therapeut Hematol Oncol &
Stem Cells Transplantat Unit;
Univ Tubingen Dept Hematol Tubingen Germany;
Wilhelminenspital Stadt Wien Ctr Oncol Vienna Austria;
Univ Calgary Southern Alberta Canc Res Inst Calgary AB Canada;
Ctr Hosp Cote Basque Bayonne France;
Univ Hosp Dept Hematol La Roche Sur Yon France;
Univ Hosp Leuven Leuven Belgium;
Barts Hlth Natl Hlth Serv Trust London England;
Hosp Univ Coimbra Coimbra Portugal;
Chonnam Natl Univ Hwasun Hosp Jeollanamdo South Korea;
Princess Margaret Hosp Toronto ON Canada;
Hosp Badalona Germans Trias &
Pujol Inst Catala Oncol Badalona Spain;
Hosp Dr Peset Valencia Spain;
Queen Elizabeth 2 Hlth Sci Ctr Halifax NS Canada;
Kantonsspital Winterthur Winterthur Switzerland;
Peking Univ Peoples Hosp Beijing Peoples R China;
Dana Farber Canc Inst Boston MA 02115 USA;
Univ Nantes Dept Hematol Nantes France;
Inst Univ Canc Toulouse France;
Univ Lorraine CHRU Nancy Nancy France;
Hop St Louis Paris France;
Chinese Acad Med Sci Blood Dis Hosp Tianjin Peoples R China;
Inst Univ Canc Toulouse Oncopole CHU Purpan Toulouse France;
Hop Claude Huriez Serv Malad Sang Lille France;
Hop Claude Huriez Serv Malad Sang Lille France;
Hop St Antoine Paris France;
CHU Rangueil Unite Genom Myelome Toulouse France;
CHU Poitiers Hop Miletrie INSERM Poitiers France;
Celgene Corp Summit NJ USA;
Celgene Corp Summit NJ USA;
Celgene Corp Summit NJ USA;
CHU Tours Hop Bretonneau Tours France;
Bordeaux Hosp Univ Ctr CHU Bordeaux Bordeaux France;
机译:阶段第3阶段对骨髓瘤升降治疗阶段的存活结果的最终分析
机译:前期氟达拉滨损害多发性骨髓瘤的干细胞收获:NMSG 13/03随机安慰剂对照II期临床试验的中期分析报告
机译:口服伊达比星,地塞米松和长春新碱治疗多发性骨髓瘤:II期临床试验的最终分析血液学
机译:PDT和VAD方案治疗多发性骨髓瘤的影响分析
机译:CD28介导的生存前信号:一种新型的治疗靶点治疗多发性骨髓瘤。
机译:对多发性骨髓瘤进行前期治疗的3期FIRST试验中生存结果的最终分析
机译:前期氟达拉滨损害多发性骨髓瘤干细胞的收获:NMSG 13/03随机安慰剂对照II期临床试验的中期分析报告